---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-325031"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2026-07-30T12:32:49+00:00"
generated_at: "2026-07-30T12:35:07.833402+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine aligns with FDA on bitopertin CRL path; APOLLO topline due Q4 2026

## Summary
- FDA Type A meeting aligned that successful Phase 3 APOLLO can serve as basis for CRL response; topline data expected Q4 2026.
- Cash, cash equivalents, and marketable securities of $717.7M as of June 30, 2026; net loss of $59.5M in Q2 2026 vs $55.2M in Q2 2025.
- RESTORE-PV Phase 2 of DISC-3405 fully enrolled; initial data now expected in Q3 2026.
- Selcodebart RALLY-MF data showed 56% major anemia response rate; end-of-Phase 2 FDA meeting expected by year-end.
- Expanded Access Program launched for bitopertin in EPP in the US and select geographies.

## SEC filing metadata
- accession: 0001193125-26-325031
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2026-07-30T12:32:49+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312526325031/0001193125-26-325031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312526325031/iron-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-325031
- JSON: https://secwatch.observer/filing/0001193125-26-325031.json
- Plain text: https://secwatch.observer/filing/0001193125-26-325031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.